Isatin come on the stage of CDK4/6 inhibitor
Pharmacy Reports · 2022
DOI: 10.51511/pr.12 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy Reports, 2022. Verfasst von Radiktya Surya Pradana und 1 weiteren Autor:innen. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved the prognosis for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer, including those with metastatic or advanced breast cancer (mBC/ABC). Recent research has focused on developing CDK4/6 inhibitors with diverse structural frameworks, including isatin-based compounds. Isatin and its derivatives have shown promise in inhibiting CDK4/6, with potential efficacy against breast cancer cell lines. Studies have also indicated that isatinyl-2-aminobenzoylhydrazone (ISABH) complexes, particularly those with transition metals like nickel (Ni-ISABH), exhibit strong binding affinities to CDK6 and fulfill key pharmacokinetic criteria.
Zitieren
APA
Pradana, R. S., & Fareza, M. S. (2022). Isatin come on the stage of CDK4/6 inhibitor. Pharmacy Reports. https://doi.org/10.51511/pr.12
Vancouver
Pradana RS, Fareza MS. Isatin come on the stage of CDK4/6 inhibitor. Pharmacy Reports. 2022. doi:10.51511/pr.12
BibTeX
@article{Pradana2022,
author = {Pradana, Radiktya Surya and Fareza, Muhammad Salman},
title = {Isatin come on the stage of CDK4/6 inhibitor},
journal = {Pharmacy Reports},
year = {2022},
doi = {10.51511/pr.12}
}
EUVIMED